Castillo MA

Language: Spanish
References: 32
Page: 519-523
PDF size: 294.03 Kb.

ABSTRACT

Gestational diabetes mellitus (GDM) is a common disorder affecting ~ 7% of pregnancies each year. It can have a much higher incidence in certain minority populations with a greater predisposition to diabetes. The disorder is characterized by carbohydrate intolerance that begins or is first recognized during pregnancy. Recognizing and treating GDM results in lowering of maternal and fetal complications. Several studies have concluded that women who do not meet established goals with diet and exercise alone have more favorable outcomes with pharmacological intervention(17.)

REFERENCES

1. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2007; 30 (1): S42-S47

2. Briggs G, Freeman R, Yaffe S: Drugs in Pregnancy and Lactation. 7th ed. Philadelphia, Lippincott, 2005, p. 1017–1020

3. Buchanan TA, Xiang A, Kjos SL, Wa tanaber R, What Is Gestational Diabe-tes?. Diabetes Care 2007; 30 (2): S105-S111

4. Checa M, Requena A, Salvador C, Tur R, Callejo J, Espinos J, et al. Insulinsensitising agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update 2005 11:375–390.

5. Coetzee EJ, Jackson WP: The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res 1986; 1:281– 287.

6. Coetzee EJ, Jackson WP: Metformin in management of pregnant insulinin dependent diabetics. Diabetologia 1979;16:241– 245.

7. Crowther CA, Hiller JE, Moss JR, McPhee, AJ, Jeffries WS, Robinson JS. Australian CarbohydrateIntolerance Study in Pregnant Women (ACHOIS) Trial Group: Effect of treatment of gestational diabetes on pregnancy outcomes. N Engl J 2005; 352:2477–2486

8. Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L: Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77:520 –525.

9. Griffith J, Conway DL. Care of diabetes in pregnancy. Obstet Gynecol Clin N Am 2004; 31: 243- 256.

10. Hague WM, PMD, Oliver D, Rowan J. Contraindications to use of metformin. BMJ 2003; 326.

11. Hellmuth E, Damm P, Molsted-Pederson L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med 2000; 17:507–511.

12. Hughes R, Rowan J. Pregnancy in women with type 2 diabetes: who takes metformin and what is the outcome? Diabet Med 2006;23:318 –322

13. Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field R. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. American Journal of Obstetrics and Gynecology 2005; 193: 118–124

14. Langer O, Yogev Y, Xenakis EMJ, Rosenn B. Insulin and glyburide therapy: Dosage, severity level of gestational dia-betes, and pregnancy outcome. American Journal of Obstetrics and Gynecology 2005); 192, 134- 139

15. Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327:951–953

16. Moore TR. Glyburide for the Treatment of Gestational Diabetes. Diabetes Care 2007; 30 ( 2): S209-S213.

17. Perkins JM, Dunn JP, Jagasia SM. Perspectives in Gestational Diabetes Mellitus: A Review of Screening, Diagnosis, and Treatment. Clinical Diabetes 2007; 25 (2): 57- 62

18. Rochon M, Rand L, Roth L, Gaddipati S. Glyburide for the management of gestational diabetes: Risk factors predictive of failure and associated pregnancy outcomes. American Journal of Obstetrics and Gynecology 2006; 195: 1090–1094

19. Rowan JA. Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial. Diabetes Care 2007; 30 ( 2): S214- S219